Effect of the qualitative composition of a high-fat diet in rats with systemic inflammatory response syndrome upon myocardial resistance to ischemic-reperfusion injury and cytokine levels

Overweight and obesity are among the main factors of cardiovascular risk, but the prospective studies on the dependence between high-fat diets and weight gain yielded contradictory results. Different types of fats exert varying metabolic effects, and this fact leads to a difference in the risk associated with increasing body weight. The effects of fat quality in the daily diet on immunological status and resistance of myocardium to ischemic-reperfusion damage should be studied experimentally in biomedical models. The purpose of this work was to assess the effect of the qualitative composition of a high-fat diet used for induction of primary visceral obesity (PVO) in rats with systemic inflammatory response syndrome (SIRS) upon myocardial resistance to ischemic-reperfusion injury, and levels of pro- and anti-inflammatory cytokines.

The experiments were performed on adult male Wistar rats with PVO caused by 28-day consumption of any fat types: hydrogenated fats (HF), vegetable oils (VO), animal fats (AF) or milk fat (MF). The SIRS model included a combination of chemically induced colitis (CIC) and intragastric injection of a broad-spectrum antimicrobial agent (AMA) for three days. Five days later, immunological and biochemical studies were conducted, as well as composition of intestinal microbiota in faecal samples, morphological changes in the structure of the large intestine, hemodynamic parameters and myocardial resistance to ischemic-reperfusion injury were studied in the model of isolated heart perfusion, by Langendorff technique.

There was a significant increase in the concentration of anti-inflammatory cytokines in animals with SIRS, i.e., TNFα, IL-1α, IL-2, IL-8, as well as a decrease in TGF-1β, an anti-inflammatory cytokine. SIRS was accompanied by severe dietary disorders and evacuatory function of the gastrointestinal tract. Minimal changes in the intestinal microbiota composition, as well as the most pronounced regeneration signs of intestinal epithelium was observed in rats in the group with MF injection. There was a trend for increasing size of infarction in all the groups as compared with control, directly correlating with increase in BDNF and IL-2 production. However, a significant increase in the infarction size was found only in the group receiving milkfat, thus suggesting a decrease in myocardial resistance to ischemic reperfusion injury (IRI).

Thus, the presence of SIRS in the primary obesity model is characterized by controllable change of inflammation markers and depends on the quality of dietary fats. The degree of morphofunctional deterioration of isolated heart, including a decrease in resistance to ischemia-reperfusion injury, correlates with the concentration of BDNF and IL-2 during the studied observation terms.

1. Borshchev Yu.Yu., Burovenko I.Yu., Karaseva A.B., Minasyan S.M., Borshchev V.Yu., Semenova N.Yu., Borshcheva O.V., Polovinkin V.V., Rodionov G.G., Suvorov A.N., Galagudza M.M. Modeling of systemic inflammatory response syndrome by chemical induction of colon injury in rats. Meditsinskaya immunologiya = Medical Immunology (Russia), 2020, Vol. 22, no. 1, pp. 87-98. (In Russ.) doi: 10.15789/1563-0625-MOS-1839.

2. Borshchev Yu.I., Ermolenko E.I. Metabolic syndrome and intestinal microecology. Translyatsionnaya meditsina = Translational Medicine, 2014, no. 1, pp. 19-28. (In Russ.)

3. Korolev D.V., Alexandrov I.V., Galagoudza M.M., Syrensky A.V., Sonin D.L., Egorova E.I. Automation of data acquisition and processing in physiological experiments. Regionarnoe krovoobrashchenie i mikrotsirkulyatsiya. = Regional Hemodynamics and Microcirculation, 2008, Vol. 7, no. 2 (26), pp. 79-84. (In Russ.)

4. Minasyan S.M., Badrihanova L.R., Galagudza M.M., Kurapeev D.I. Comparative research of protective effect of a hypothermia, ischemic preconditioning and the modified cardioplegic solutions at ischemia-reperfusion of the rat's isolated heart. Regionarnoe krovoobrashchenie i mikrotsirkulyatsiya = Regional Hemodynamics and Microcirculation, 2008, Vol. 7, no. 2, pp. 72-78. (In Russ.)

5. Moskalev A.V., Rudoy A.S., Apchel A.V., Zueva V.O., Kazimova O.E. Features of biology of transforming growth factor в and immunopathology. Vestnik rossiyskoy voenno-meditsinskoy akademii = Bulletin of the Russian Military Medical Academy, 2016, no. 2 (54), pp. 206-216. (In Russ.)

6. Serebryanya N.B., Lipatova L.V., Sivakova N.A., Vasilenko A.V. The recombinant human interleukin-2 (IL-2) as the agent of antiepileptic therapies. Rossiyskiy immunologicheskiy zhurnal = Russian Journal of Immunology, 2014, Vol. 8, no. 3, pp. 723-726. (In Russ.)

7. Simbirtsev A.S. Interleukin-2 and interleukin-2 receptor complex in the regulation of immunity. Immunologiya = Immunologiya, 1998, no. 3, pp. 3-8. (In Russ.)

8. Simbirtsev A.S. Interleukin-8 and other chemokines. Immunologiya = Immunologiya, 1999, no. 4, pp. 9-14. (In Russ.)

9. Ugolev A.M. Membrane digestion. Polysubstrate processes, organization and regulation. Leningrad: Nauka, 1972. 356 p.

10. Fomicheva E.E., Shanin S.N., Filatenkova T.A., Serebryanaya N.B. IL-2 and regulation of stress hormones and BDNF neurotropic factor levels after experimental traumatic brain injury (TBI). Meditsinskaya immunologiya = Medical Immunology (Russia), 2020, Vol. 22, no. 4, pp. 647-656. (In Russ.) doi: 10.15789/1563-0625-IAR-1973.

11. Abbas A.K., Trotta E., Simeonov D., Marson A., Bluestone J.A. Revisiting IL-2: Biology and therapeutic prospects. Sci. Immunol., 2018, Vol. 3, Iss. 25, pii: eaat1482. doi: 10.1126/sciimmunol.aat1482.41.

12. Alhazmi A., Stojanovski E., McEvoy M., Garg M.L. Macronutrient intakes and development of type 2 diabetes: a systematic review and meta-analysis of cohort studies. J. Am. Coll. Nutr., 2012, no. 31, pp. 243-258.

13. Braun E.S., Crawford F.W., Desai M.M., Meek J., Kirley P.D., Miller L., Anderson E.J., Oni O., Ryan P., Lynfield R., Bargsten M., Bennett N.M., Lung K.L., Thomas A., Mermel E., Lindegren M.L., Schaffner W., Price A., Chaves S.S. Obesity not associated with severity among hospitalized adults with seasonal influenza virus infection. Infection, 2015, Vol. 43, no. 5, pp. 569-575.

14. Carrero J.J., Park S.H., Axelsson J., Lindholm B., Stenvinkel P. Cytokines, atherogenesis, and hypercatabolism in chronic kidney disease: a dreadful triad. Semin Dial., 2009, Vol. 22, no. 4, pp. 381-386.

15. Chowdhury R., Warnakula S., Kunutsor S., Crowe F., Ward H.A., Johnson L., Franco O.H., Butterworth A.S., Forouhi N.G., Thompson S.G., Khaw K.T., Mozaffarian D., Danesh J., Di Angelantonio E. Association of dietary, circulating, and supplement fatty acids with coronary risk: a systematic review and meta-analysis. Ann. Intern. Med., 2014, no. 160, pp. 398-406.

16. Degirolamo C., Shelness G.S., Rudel L.L. LDL cholesteryl oleate as a predictor for atherosclerosis: evidence from human and animal studies on dietary fat. J. Lipid Res., 2009, 50 Suppl. (Suppl.), pp. 434-439.

17. Jakobsen M.U., Dethlefsen C., Joensen A.M., Stegger J., Tj0nneland A., Schmidt E.B., Overvad K. Intake of carbohydrates compared with intake of saturated fatty acids and risk of myocardial infarction: importance of the glycemic index. Am. J. Clin. Nutr., 2010, Vol. 91, no. 6, pp. 1764-1768.

18. Dietary Guidelines Advisory Committee; Scientific Report of the 2015 Dietary Guidelines Advisory Committee, 2015. Available at: http://www.health.gov/dietaryguidelines/2015-scientific-report/.

19. Dinarello CA. Proinflammatory cytokines. Chest, 2000, Vol. 118, no. 2, pp. 503-508.

20. Dinarello C.A., Cannon J.G., Mier J.W., Bernheim H.A., LoPreste G., Lynn D.L., Love R.N., Webb A.C., Auron P.E., Reuben R.C. Multiple biological activities of human recombinant interleukin 1. J. Clin. Invest., 1986, Vol. 77, no. 6, pp. 1734-1739.

21. Fahey T.J. 3rd, Sherry B., Tracey K.J., van Deventer S., Jones W.G. 2nd, Minei J.P., Morgello S., Shires G.T., Cerami A. Cytokine production in a model of wound healing: the appearance of MIP-1, MIP-2, cachectin/TNF and IL-1. Cytokine, 1990, Vol. 2, no. 2, pp. 92-99.

22. Frieden T.R., Berwick D.M. The “Million Hearts” initiative - preventing heart attacks and strokes. N. Engl. J. Med., 2011, Vol. 365, no. 13, e27. doi: 10.1097/01.NPR.0000476372.04620.7a.

23. Geleijnse J.M., de Goede J., Brouwer I.A. Alpha-linolenic acid: is it essential to cardiovascular health? Curr. Atheroscler. Rep., 2010, no. 12, pp. 359-367.

24. Himmerich H., Fischer J., Bauer K., Kirkby K.C., Sack U., Krugel U. Stress-induced cytokine changes in rats. Eur. Cytokine Netw., 2013, Vol. 24, no. 2, pp. 97-103.

25. Huttunen R., Karppelin M., Syrjanen J. Obesity and nosocomial infections. J. Hosp. Infect., 2013, Vol. 85, no. 1, pp. 8-16.

26. Jakobsen M.U., O'Reilly E.J., Heitmann B.L., Pereira M.A., Balter K., Fraser G.E., Goldbourt U., Hallmans G., Knekt P., Liu S., Pietinen P., Spiegelman D., Stevens J., Virtamo J., Willett W.C., Ascherio A. Major types of dietary fat and risk of coronary heart disease: a pooled analysis of 11 cohort studies. Am. J. Clin. Nutr., 2009, no. 89, pp. 1425-1432.

27. James W.P.T., Jackson-Leach R., Mhurchu C.N., Kalamara E., Shayeghi M., Rigby N.J., Nishida C., Rodgers A. Overweight and obesity (high body mass index). In: Ezzati M et al., eds. Comparative quantification of health risks: global and regional burden of disease attribution to selected major risk factors, Vol. 1. Geneva, World Health Organization, 2004, pp. 497-596.

28. Kaspersen K.A., Pedersen O.B., Petersen M.S., Hjalgrim H., Rostgaard K., M0ller B.K., Juul-S0rensen C., Kotze S., Dinh K.M., Erikstrup L.T., S0rensen E., Th0rner L.W., Burgdorf K.S., Ullum H., Erikstrup C. Obesity and risk of infection: results from the Danish Blood Donor Study. Epidemiology, 2015, Vol. 26, no. 4, pp. 580-589.

29. Kumar M., Dhaka P., Vijay D., Vergis J., Mohan V., Kumar A., Kurkure N.V., Barbuddhe S.B., Malik S.V., Rawool D.B. Antimicrobial effects of Lactobacillus plantarum and Lactobacillus acidophilus against multidrugresistant enteroaggregative Escherichia coli. Int. J. Antimicrob. Agents, 2016, Vol. 48, no. 3, pp. 265-270.

30. Marmot M., Wilkinson R., eds. Social Determinants of Health. 2nd edition ed. Oxford University Press, 2005. Available at: https://oxford.universitypressscholarship.com/view/10.1093/acprof:oso/9780198565895.001.0001/acprof-9780198565895.

31. Mozaffarian D., Micha R., Wallace S. Effects on coronary heart disease of increasing polyunsaturated fat in place of saturated fat: a systematic review and meta-analysis of randomized controlled trials. PLoS Med., 2010, no. 7, e1000252. doi: 10.1371/journal.pmed.1000252.

32. Mozaffarian D. Diverging global trends in heart disease and type 2 diabetes: the role of carbohydrates and saturated fats. Lancet Diabetes Endocrinol., 2015, Vol. 3, no. 8, pp. 586-588.

33. Pan A., Chen M., Chowdhury R., Wu J.H., Sun Q., Campos H., Mozaffarian D., Hu F.B. alpha-Linolenic acid and risk of cardiovascular disease: a systematic review and meta-analysis. Am. J. Clin. Nutr., 2012, no. 96, pp. 1262-1273.

34. Peveri P., Walz A., Dewald B., Baggiolini M. A novel neutrophil-activating factor produced by human mononuclear phagocytes. J. Exp. Med., 1988, Vol. 167, pp. 1547-1259.

35. Prentice A.M., Jebb S.A. Energy intake/physical activity interactions in the homeostasis of body weight regulation. Nutr. Rev., 2004, Vol. 62, pp. S98-S104.

36. Sato Y., Ohshima T. The expression of mRNA of proinflammatory cytokines during skin wound healing in mice: a preliminary study for forensic wound age estimation (II). Int. J. Legal. Med., 2000, Vol. 113, pp. 140-145.

37. Schroeder J., Mrowietz U., Morita E., Christophers E. Purification and biochemical characterization of a human monocyte derived neutrophil activating peptide that lacks interleukin-1 activity. J. Immunol., 1987, Vol. 139, pp. 3474-3483.

38. Schwingshackl L., Hoffmann G. Monounsaturated fatty acids, olive oil and health status: a systematic review and metaanalysis of cohort studies. Lipids Health Dis., 2014, Vol. 13, 154.

39. Seidell J.C. Dietary fat and obesity: an epidemiologic perspective. Am. J. Clin. Nutr., 1998, Vol. 67 (Suppl. 3), pp. 546S-550S.

40. Storlien L.H., Huang X.F., Lin S., Xin X., Wang H.Q., Else P.L. Dietary fat subtypes and obesity. World Rev. Nutr. Diet., 2001, Vol. 88, pp. 148-154.

41. Tordjman J., Guerre-Millo M., Clement K. Adipose tissue inflammation and liver pathology in human obesity. Diabetes Metab., 2008, Vol. 34, no. 6 (Pt 2), pp. 658-663.

42. Ulich T.R., Yin S., Guo K., Yi E.S., Remick D., del Castillo J. Intratracheal injection of endotoxin and cytokines. II. Interleukin-6 and transforming growth factor beta inhibit acute inflammation. Am. J. Pathol., 1991, Vol. 138, no. 5, pp. 1097-1101.

43. US Food and Drug Administration, FDA Cuts Trans Fat in Processed Foods, 2015. Available at: http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm372915.htm.

44. Utzolino S., Ditzel C.M., Baier P.K., Hopt U.T., Kaffarnik M.F. The obesity paradox in surgical intensive care patients with peritonitis. J. Crit. Care, 2014, Vol. 29, no. 5, pp. 887.e1-5.

45. Visscher T.L., Seidell J.C. The public health impact of obesity. Annu. Rev. Public Health, 2001, Vol. 22, pp. 355-375.

46. Werner S., Grose R. Regulation of wound healing by growth factors and cytokines. Physiol. Rev., 2003, Vol. 83, pp. 835-870.

47. Wu J.H., Micha R., Imamura F., Pan A., Biggs M.L., Ajaz O., Djousse L., Hu F.B., Mozaffarian D. Omega-3 fatty acids and incident type 2 diabetes: a systematic review and meta-analysis. Br. J. Nutr., 2012, Vol. 107, Suppl. 2, pp. S214-S227.